Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CAR-T therapies

This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.

Gilead signs $3bn-plus gene-editing deal with Sangamo

Gilead signs $3bn-plus gene-editing deal with Sangamo

The company seems determined to stay in the forefront of the pharma industry’s push into cell therapies, with the latest deal coming shortly after it acquired CAR-T specialist Kite ... to ten off-the-shelf (allogeneic) as well as autologous CAR-T

Latest news

  • Is acquisitive Celgene now eyeing CAR-T specialist Juno? Is acquisitive Celgene now eyeing CAR-T specialist Juno?

    That alliance covers chimeric antigen receptor T cell (CAR-T) therapies, including Juno’s lead candidate JCAR017 which is in the final stages of development and could get its first approvals ... Interest in CAR-T therapies in particular has been

  • Spark’s Luxturna becomes US’s first approved gene therapy Spark’s Luxturna becomes US’s first approved gene therapy

    two CAR-T therapies for blood cancers which involve genetically modifying cells outside the body. ... Novartis’first-approved CAR-T therapy Kymriah (tisagenleucel) has been priced at $475, 000 per course in the US, but a recent Bloomberg report

  • Gilead adds to CAR-T assets with Cell Design Labs buyout Gilead adds to CAR-T assets with Cell Design Labs buyout

    The new deal adds new technologies that could form the basis of a new generation of CAR-T therapies, according to Gilead. ... Lim’s team has been working on ways to introduce some degree of control over CAR-T therapies, which while showing spectacular

  • CAR-T therapies show long-term benefits in lymphoma CAR-T therapies show long-term benefits in lymphoma

    CAR-T therapies show long-term benefits in lymphoma. Novartis’Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients. ... CAR-T therapies from Novartis and Gilead took centre stage at the American Society of

  • Price matters Price matters

    Go ahead. Ask. The number of people answering ‘yes’is pretty low - isn’t it? ... And so, in this brave new world of CAR-T and CRISPR and I/O therapies - to name a few - we continue to rely on governments to ensure that these therapies

More from news
Approximately 3 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... It will also be interesting to see how gene therapies and cell-based therapies,

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    The data for the research was derived from published data on CAR-T pipeline therapies, but was not related to any particular product. ... transplant. As a result, there may be no existing mechanism for these centres to obtain funding for any additional,

  • Deal Watch November 2016 Deal Watch November 2016

    were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy. ... their own CAR T cell therapies - so CAR T cell therapy seems to be still alive and doing well.

  • Deal Watch September 2016 Deal Watch September 2016

    The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 800. Arrowhead / Amgen. Licences. 2 agreements to develop and

  • Deal Watch April 2016 Deal Watch April 2016

    Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies. ... 61. Celgene (US). Juno (US). Option exercised to extend territory. Phase II CD19-based CAR T therapies

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia